Data Insights

Fruquintinib by Takeda Pharmaceutical for Angiosarcoma: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Angiosarcoma

Data Insights

Fruquintinib by Takeda Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Metastatic Pancreatic Cancer

Data Insights

Mezagitamab by Takeda Pharmaceutical for IgA Nephropathy (Berger's Disease): Likelihood of Approval

Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase I for IgA Nephropathy (Berger's Disease). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mezagitamab in IgA Nephropathy (Berger's Disease)

Data Insights

TAK-012 by Takeda Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

TAK-012 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...

Data Insights

TAK-012 by Takeda Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval

TAK-012 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Data Insights

(Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + Protein C (human)) by Takeda Pharmaceutical for Blood Coagulation: Likelihood of Approval

(Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) +...

Likelihood of Approval and Phase Transition Success Rate Model - (Coagulation Factor II (human) + Coagulation Factor VII (human) + Coagulation Factor IX (human) + Coagulation Factor X (human) + Protein C (human)) in Blood Coagulation

Data Insights

TAK-186 by Takeda Pharmaceutical for Pancreatic Cancer: Likelihood of Approval

TAK-186 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Data Insights

(Hyaluronidase (recombinant, human) + immune globulin (human)) by Takeda Pharmaceutical for Lymphoma: Likelihood of Approval

(Hyaluronidase (recombinant, human) + immune globulin (human)) is under clinical development by Takeda Pharmaceutical and currently in Phase II for...

Data Insights

Mezagitamab by Takeda Pharmaceutical for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval

Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....

Likelihood of Approval and Phase Transition Success Rate Model - Mezagitamab in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Data Insights

Soticlestat by Takeda Pharmaceutical for Lennox-Gastaut Syndrome: Likelihood of Approval

Soticlestat is under clinical development by Takeda Pharmaceutical and currently in Phase III for Lennox-Gastaut Syndrome. According to GlobalData, Phase...

Data Insights

Subasumstat by Takeda Pharmaceutical for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

Subasumstat by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Non-Small Cell Lung Cancer

Data Insights

Subasumstat by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Solid Tumor

Data Insights

Subasumstat by Takeda Pharmaceutical for Cervical Cancer: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Cervical Cancer

Data Insights

Mezagitamab by Takeda Pharmaceutical for Myasthenia Gravis: Likelihood of Approval

Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mezagitamab in Myasthenia Gravis

Data Insights

Dazostinag by Takeda Pharmaceutical for Oropharyngeal Cancer: Likelihood of Approval

Dazostinag is under clinical development by Takeda Pharmaceutical and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...

Data Insights

Dazostinag by Takeda Pharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Dazostinag is under clinical development by Takeda Pharmaceutical and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Data Insights

Dazostinag by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval

Dazostinag is under clinical development by Takeda Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Data Insights

Dazostinag by Takeda Pharmaceutical for Colorectal Cancer: Likelihood of Approval

Dazostinag is under clinical development by Takeda Pharmaceutical and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Data Insights

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...